Life Sciences

  • November 14, 2025

    DC Circ. Wary Of DEA Delays In Religious Ayahuasca Case

    A D.C. Circuit panel on Friday appeared skeptical that the Drug Enforcement Administration was justified in its delays processing an Iowa church's application for a religious exemption to the Controlled Substances Act to use a psychedelic in its rites.

  • November 14, 2025

    Taxation With Representation: Wachtell, Paul Hastings, Sidley

    In this week's Taxation With Representation, Pfizer Inc. completes its acquisition of obesity drug developer Metsera Inc., motion and controls technologies company Parker-Hannifin Corp. acquires Filtration Group Corp., and fund administrator JTC PLC backs a cash offer in the billions from British private equity shop Permira.

  • November 14, 2025

    Photographer Sues Gilead For Continued Use Of Ad Images

    A photographer sued Gilead Sciences Inc., claiming the pharmaceutical giant had used a set of images he'd taken for an advertisement series long after it knew its license for the photos expired.

  • November 14, 2025

    Purdue's $7.4B Ch. 11 Plan To Be Confirmed

    A New York bankruptcy judge agreed to confirm the $7.4 billion Chapter 11 plan of Purdue Pharma LP on Friday, saying he would issue a formal bench ruling next Tuesday explaining his decision.

  • November 14, 2025

    Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy

    Gibson Dunn & Crutcher LLP-advised Merck on Friday said it will broaden its respiratory portfolio with a $9.2 billion deal to buy Cooley LLP-led Cidara Therapeutics, betting that an investigational antiviral could help the company tackle the global health burden of seasonal influenza.

  • November 13, 2025

    J&J Bellwether Trial Over Talc Cancer Risks Kicks Off In LA

    An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a Los Angeles jury Thursday during opening statements in a bellwether trial that decades-old internal documents prove J&J knew its talc products contained toxic levels of asbestos but hid that information.

  • November 13, 2025

    Hemp Policy At Crossroads After Government Reopening Bill

    Hemp industry advocates are pledging to use the one-year gap between enactment and implementation of the government funding agreement, which effectively recriminalized most hemp-derived THC products, to craft new regulatory legislation that stops short of a full ban.

  • November 13, 2025

    NC Biz Court Bulletin: Rulings Spotlight Coverage Clashes

    The North Carolina Business Court plowed into the fourth quarter with two big decisions in insurance disputes that involved $50 million in COVID-19-related losses at a chain of outlet malls, and an industrial accident at a Nucor Corp. iron plant in Louisiana.

  • November 13, 2025

    Weight-Loss Drug MDL In Pa. Grows With 3 New Jersey Cases

    Three New Jersey cases were grouped into multidistrict litigation accusing Eli Lilly & Co. and Novo Nordisk of downplaying alleged side effects of weight loss drugs like Ozempic and Trulicity, according to a transfer order filed in Pennsylvania federal court.

  • November 13, 2025

    Mich. Schools Sue Over Privacy Waiver In Funding Bill

    A group of school districts and leaders have sued the state of Michigan in state and federal courts, asking judges to bar the state from enforcing a portion of a recently passed school funding legislative package that would require schools to give up privacy privileges in mass casualty events to receive mental health or safety dollars.

  • November 13, 2025

    Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal

    Pediatric cancer-focused biopharmaceutical company Day One Biopharmaceuticals, led by Fenwick & West LLP, announced plans Thursday to acquire clinical-stage biopharmaceutical company Mersana Therapeutics Inc., advised by WilmerHale, in a take-private deal worth up to $285 million.

  • November 13, 2025

    3rd Circ. Says Quest Didn't Eavesdrop In Data Privacy Suit

    The Third Circuit on Thursday upheld a win for Quest Diagnostics, which beat a class action alleging it inappropriately shared patient data with Meta Platforms through ad tracking software on its website, with the court reasoning that information was not unlawfully collected because it wasn't obtained through eavesdropping.

  • November 13, 2025

    Wachtell-Led Pfizer Closes Metsera Deal Worth Up To $10B

    Pfizer Inc. said Thursday that it has successfully completed its acquisition of Metsera Inc., securing the obesity drug developer after a tumultuous bidding war with Novo Nordisk and court fights that redirected the deal in Pfizer's favor.

  • November 13, 2025

    FTC Fails To Block Doctors' Testimony In $945M Merger Case

    A D.C. federal judge refused Thursday to bar a pair of outside doctors and consultants from vouching for Edwards Lifesciences Corp.'s planned JenaValve Technology Inc. acquisition, preferring to let the Federal Trade Commission contest their testimony in cross-examination and saying from the bench that he'll "make some popcorn."

  • November 13, 2025

    Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL

    A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.

  • November 12, 2025

    Biotech Co., Founders Can't Duck $14.3M SEC Payment

    A Colorado federal judge has rejected a biotech startup and two of its founders' bid to reconsider a February order requiring them to pay the U.S. Securities and Exchange Commission more than $14.3 million for overstating their own investments in the company.

  • November 12, 2025

    Valsartan Cancer Expert Blocked, Ending First Injury Trial

    What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.

  • November 12, 2025

    Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC

    Sandoz Inc. and its marketing firm RareGen LLC urged a Third Circuit panel on Wednesday to reinstate the full $137.2 million awarded in breach of contract damages against United Therapeutics Corp., claiming a lower court's decision to halve the damages provided a windfall to their adversary.

  • November 12, 2025

    NJ Justices Keep Ozempic Injury Mass Torts Separate

    The New Jersey Supreme Court has decided not to combine two Bergen County Superior Court mass tort cases over weight loss drugs including Ozempic, Wegovy and Mounjaro, keeping them separate based on the type of injury alleged.

  • November 12, 2025

    Purdue Kicks Off Ch. 11 Confirmation With Plan Overview

    Bankrupt OxyContin maker Purdue Pharma began its Chapter 11 confirmation trial Wednesday with an overview of its latest plan and the myriad settlements that underpin the proposal, including a $6.5 billion commitment from the company's owners.

  • November 12, 2025

    Judge Confirms $620K Award In Radiology Contract Dispute

    A Georgia federal judge on Wednesday upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, rejecting the latter's bid to vacate the decision by claiming an arbitrator misinterpreted their long-standing services agreement.

  • November 12, 2025

    1st Circ. Weighs Federal Halt To Planned Parenthood Funding

    First Circuit judges skeptically questioned a Planned Parenthood attorney Wednesday as they wrestled with whether Congress illegally singled out the organization in budget legislation that blocks its federal Medicaid funding for a year.

  • November 12, 2025

    China Continues To Drive Surge In Global Patent Applications

    The number of patent applications filed worldwide in 2024 surged, continuing years of growth due in significant part to filings out of China, according to a World Intellectual Property Organization report released Wednesday.

  • November 12, 2025

    China National Gets Time Served For Smuggling Crop Fungus

    A Chinese scholar with research ties to the University of Michigan will likely leave the United States this week after she was sentenced on Wednesday to time served following five months in custody for smuggling into the country a fungus that causes crop disease and lying about it to federal agents.

  • November 12, 2025

    Judge Won't Halt Injunction Blocking Trump's Trans Care Ban

    A Washington federal judge rejected the Trump administration's bid to halt a temporary injunction, saying the president took too long to request a pause in the order, which blocks federal officials from withholding federal healthcare funds to hospitals in four states that provide gender-affirming care. 

Expert Analysis

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • Ruling On Labor Peace Law Marks Shift For Cannabis Cos.

    Author Photo

    Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.

  • Fed. Circ. Rulings Refine Patent Claim Construction Standards

    Author Photo

    Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.

  • How Value-Based Patent Fees May Shape IP Strategies

    Author Photo

    If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary.

  • Agentic AI Puts A New Twist On Attorney Ethics Obligations

    Author Photo

    As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.

  • Using Reissue Applications To Strategically Improve Patents

    Author Photo

    Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield.

  • FDA Transparency Plans Raise Investor Disclosure Red Flags

    Author Photo

    The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Patent Claim Lessons From Fed. Circ.'s Teva Decision

    Author Photo

    The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.

  • Series

    Law School's Missed Lessons: Adapting To The Age Of AI

    Author Photo

    Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.

  • Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning

    Author Photo

    A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.

  • DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech

    Author Photo

    The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.

  • Future-Proof Patent Law By Starting Talent Pipelines Early

    Author Photo

    Law firms struggling with a narrow talent pipeline in the intellectual property space should consider beginning their recruitment strategies for potential candidates as early as high school, and raise awareness for career opportunities that do not require a law degree, says Christine Hollis at Marshall Gerstein.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.